Latest Conference Articles

More Data Needed on Changing Systemic Therapy in NSCLC

There is limited data on when and whether oncologists should change systemic therapy for patients with non–small cell lung cancer, but some studies provide useful guidance.

Biomarkers and Histology Play Key Roles in Frontline Metastatic NSCLC Options

In light of recent advancements, the current paradigm for choosing first-line therapy for patients with metastatic non–small cell lung cancer who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology.

Herbst Highlights Next Steps With Immunotherapy in Lung Cancer

Roy S. Herbst, MD, PhD, discusses where future research is headed for immunotherapy in lung cancer.

Dr. Hanna on Consolidation Immunotherapy in Stage III NSCLC

Nasser Hanna, MD, Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research, at Indiana University Melvin and Bren Simon Cancer Center, discusses the efficacy of consolidation immunotherapy in patients with stage III non–small cell lung cancer.

Dr. Herbst on Immune Resistance in Lung Cancer

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.

Broad Panel NGS Testing Grows in Value for NSCLC

Although driver mutations have been identified for significant NSCLC subsets, patients with metastatic disease benefit from broad panel next-generation sequencing testing because of the growing clinical relevance of less common alterations and gene signatures.

Dr. Perez-Soler on Efficiency of NGS in Lung Cancer

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the efficiency of next-generation sequencing in lung cancer.

Camidge Breaks Down Oncogene-Driven NSCLC

D. Ross Camidge, MD, PhD, discusses the crowded landscape of oncogene-driven non­–small cell lung cancer.

Dr. Borghaei on Second-Line Therapy in SCLC

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the evolving second line of treatment in small cell lung cancer.

Dr. Kris on Adjuvant Systemic Therapy in NSCLC

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses adjuvant systemic therapy in patients with non–small cell lung cancer.

Dr. Camidge on Optimal Therapy in EGFR+ NSCLC

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non–small cell lung cancer.

Acquired Resistance Remains Key Challenge in Oncogene-Driven NSCLC

Balazs Halmos, MD, MS, discusses overcoming acquired resistance and other next steps needed to advance the oncogene-driven non–small cell lung cancer paradigm.

Uncertainty Surrounds Nondriver NSCLC Treatment After Progression

Hossein Borghaei, DO, MS, discusses current and potential therapeutic approaches for patients with non-oncogene driven lung cancer who progress on frontline treatment.

Drilon Sheds Light on Lesser-Known Markers in NSCLC

Alexander E. Drilon, MD, discusses developing markers in the non–small cell lung cancer paradigm.

Dr. Vij on Maintenance and Consolidation in Newly Diagnosed Multiple Myeloma

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the use of maintenance and consolidation in multiple myeloma.

Dr. Ghobadi on the Potential Development of CAR T Cells in Solid Tumors

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.

Dr. Iqbal on the Biggest Advance in the Treatment of Neuroendocrine Tumors

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the impact of peptide receptor radionuclide therapy (PRRT) on the treatment of patients with neuroendocrine tumors (NETs).

Dr. Barzi on Available and Emerging Neoadjuvant Approaches in Pancreatic Cancer

Afsaneh Barzi, MD, assistant professor of clinical medicine, Norris Comprehensive Cancer Center, University of Southern California, discusses available and emerging neoadjuvant strategies for the treatment of patients with nonmetastatic pancreatic cancer.

Dr. Dean on the Evolution of Treatment Approaches in MCL

Robert Dean, MD, staff physician, Cleveland Clinic, discusses the evolution of treatment approaches in mantle cell lymphoma (MCL).

Treatment Updates Move Neuroendocrine Tumor Paradigm Forward

Syma Iqbal, MD, discusses the evolving treatment paradigm of neuroendocrine tumors.

Role of Immunotherapy May Expand in Gastric/GEJ Cancers

The second-line treatment of gastric and gastroesophageal junction cancers has shifted considerably in the last few years, due in part to the addition of immunotherapy for select subgroups of patients.

Kahl Highlights Frontline Considerations in Changing CLL Landscape

Brad Kahl, MD, discusses the rapidly evolving therapeutic landscape of CLL and the novel combinations on the horizon.

Reach of CAR T-Cell Therapy Poised to Extend in Oncology

Armin Ghobadi, MD, discusses the evolution and expansion of CAR T-cell therapy in oncology and how to maximize its application across liquid and solid tumors.

Treatment Regimens to Be Refined in Hodgkin Lymphoma

Nancy L. Bartlett, MD, discusses factors in treatment decisions for patients with advanced-stage Hodgkin lymphoma.

Dr. Bartlett on Treatment Regimens for Patients With Hodgkin Lymphoma

Nancy Bartlett, MD, Koman Chair in Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses treatment regimens for patients with Hodgkin lymphoma.

Dr. Lenz on the Benefit of Regorafenib in CRC

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the benefit of regorafenib (Stivarga) in the treatment of patients with colorectal cancer (CRC).

Dr. Kahl on the Impact of Venetoclax in Chronic Lymphocytic Leukemia

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the impact of venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Choueiri on the Impact of the JAVELIN Renal 101 Findings in RCC

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the impact of the JAVELIN Renal 100 trial on the treatment landscape of renal cell carcinoma.

Dr. Mehanna on the Updated Staging System for HPV+ Head and Neck Cancer

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery director, Institute of Head and Neck Studies and Education at the School of Cancer Studies, University of Birmingham, discusses the new staging system for patients with HPV-positive head and neck cancer.

Dr. Kim Discusses the Primary Efficacy Results From the B-F1RST Trial in NSCLC

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the primary efficacy results from the B-F1RST trial in non–small cell lung cancer (NSCLC).